By Adam Rhodes ( February 14, 2018, 2:13 PM EST) -- Nektar Therapeutics has inked a $1.85 billion cash-and-stock deal to jointly develop and manage its cancer-fighting, immuno-stimulatory therapy in combination with two Bristol-Myers Squibb cancer treatments, the companies said Wednesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.